Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cinoxacin
- Development stage
- Discontinued
- Lead developer
- Eli Lilly
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Cinoxacin is a synthetic antibacterial agent belonging to the first-generation quinolone class. It was primarily used for the prevention and treatment of initial and recurrent urinary tract infections (UTIs) in adults, especially those caused by susceptible gram-negative bacteria such as Escherichia coli, Proteus mirabilis, Proteus vulgaris, Klebsiella species (including K. pneumoniae), and Enterobacter species[3][4][8]. Its mechanism of action involves inhibiting bacterial DNA gyrase (a type II topoisomerase) and topoisomerase IV, enzymes essential for DNA replication and cell division; this results in inhibition of bacterial DNA synthesis and is bactericidal[4][5][6][7]. Cinoxacin achieves high urinary concentrations after oral administration but has been discontinued in many countries due to the availability of newer agents with improved safety profiles[5]. The drug was developed by Eli Lilly.
- Brand names
- Cinobac
- Other names
- cinoxacin
02
Targets
DNA gyraseTopo IV (Bacterial Topoisomerase IV)
Beyond the preview
Go deeper on cinoxacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cinoxacin.